OPRX250117C17500
- 0.00
- 0.000.00%
OptimizeRx Newsroom
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $13
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
Optimistic Buy Rating for OptimizeRx Amid Leadership Transition and Strong Financial Outlook
OptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range
Express News | OptimizeRx Corp: Reaffirms Its Financial Guidance for Full Year 2024
Press Release: OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
Express News | OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
Stephens Maintains OptimizeRx(OPRX.US) With Hold Rating, Cuts Target Price to $5.5
The Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts
Express News | OptimizeRx Corp : Stephens Initiates Coverage With Equal Weight Rating; Target Price $5.50
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $11
Analysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)
Even With A 30% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx Corporation (NASDAQ:OPRX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
12 Health Care Stocks Moving In Thursday's Pre-Market Session
OptimizeRx | 10-Q: Q3 2024 Earnings Report
OptimizeRx Shares Slump After 3Q Results Miss Estimates, Cuts Outlook